Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522

Clinical Pharmacokinetics

Volumn 45, Issue 3, 2006, Pages 297-303

  Wise, Stephen ^a   Yuen, Eunice ^a   Chan, Clark ^a   Yeo, Kwee Poo ^a   Teng, Lorraine ^a   Lau, Titus ^b   Voelker, James ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; N NORRUBOXISTAURIN; RUBOXISTAURIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ALGORITHMS; AREA UNDER CURVE; BIOTRANSFORMATION; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; KIDNEY FAILURE, CHRONIC; MALE; MALEIMIDES; RENAL DIALYSIS;

EID: 33644657206     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645030-00005     Document Type: Article

References (16)

1. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13-[(Dimethylamino) methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3, 4-h][1,4,13] oxadiazacyclo-hexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J Med Chem 1996 Jul; 39 (14): 2664-71
2. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Opthalmol 2002 Dec; 47 Suppl. 2: S263-9
3. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003 Sep; 42 (3): 456-65
4. Engel GL, Farid NA, Faul MM, et al. Salt form selection and characterization of ruboxistaurin mesylate monohydrate. Int J Pharm 2000 Apr 5; 198 (2): 239-47
5. Tesfamariam B, Brown ML, Deykin D, et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990 Mar; 85 (3): 929-32
6. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992 Nov; 89 (22): 11059-63
7. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996 May; 272 (5262): 728-31
8. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997 Sep; 46 (9): 1473-80
9. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999 Oct; 48 (10): 2090-5
10. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000 Aug; 41 (9): 2702-6
11. Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997 Jul; 100 (1): 115-26
12. Molecule of the month: ruboxistaurin mesilate hydrate. Drug News Perspect 2003 Dec; 16 (10): 691
13. Ring BJ, Gillespie JS, Binkley SN, et al. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos 2002 Sep; 30 (9): 957-61
14. Demolle D, de Suray JM, Vandenhende F, et al. LY333531 single escalating oral dose study in healthy volunteers [abstract]. Diabetologia 1998; 41 Suppl. 1: A283
15. Burkey JL, Campanale KM, O'Bannon DD, et al. Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 2002 Nov; 32 (11): 1045-52
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41